Compugen Ltd.
CGEN
Rank in Stocks
#16711
Compugen Ltd. is a clinical-stage biotechnology company engaged in the... Compugen Ltd. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative therapeutic candidates across Israel, the United States, and Europe. The company's primary focus is immuno-oncology, with a robust pipeline of investigational treatments. Key assets in their immuno-oncology portfolio include: COM701, an anti-PVRIG antibody, currently in Phase I clinical trials for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, also in Phase I, being evaluated as a monotherapy in patients with advanced malignancies. Bapotulimab, an antibody designed to target ILDR2, which is undergoing Phase I clinical study for solid tumors. AZD2936, a novel bispecific antibody that targets both TIGIT and PD-1, advancing through Phase I/II clinical studies in patients with advanced or metastatic non-small cell lung cancer. Beyond these clinical-stage programs, Compugen is also pursuing early-stage immuno-oncology research, with a particular emphasis on myeloid targets. The company maintains significant strategic alliances, including: A collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against Compugen's proprietary immune checkpoint regulators. A partnership with Bristol-Myers Squibb to assess the safety and tolerability of COM701 when combined with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in advanced solid tumor patients. An engagement with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets. A licensing agreement with AstraZeneca for the development of bispecific and multispecific immuno-oncology antibody products. A research collaboration with Johns Hopkins University focusing on myeloid research. Compugen Ltd. was founded in 1993 and is headquartered in Holon, Israel.
Share Price
$2.14
Last synced: 2026-11-09
Market Cap
$197.09M
Change (1 day)
9.18%
Change (1 year)
24.42%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Compugen Ltd. (CGEN)
Category
Healthcare
EPS for Compugen Ltd. (CGEN)
EPS as of June 2026 TTM: $0.38
According to Compugen Ltd.'s latest financial reports, its current EPS (TTM) is $0.38. At the end of 2025 the company had an EPS of $0.38, an increase over its 2024 EPS of $-0.16.
EPS history for Compugen Ltd. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.38 | 0.00% |
| 2025 | $0.38 | -337.50% |
| 2024 | $-0.16 | -23.81% |
| 2023 | $-0.21 | -46.15% |
| 2022 | $-0.39 | -4.88% |
| 2021 | $-0.41 | 10.81% |
| 2020 | $-0.37 | -13.95% |
| 2019 | $-0.43 | 4.88% |
| 2018 | $-0.41 | -43.06% |
| 2017 | $-0.72 | 16.13% |
| 2016 | $-0.62 | 55.00% |
| 2015 | $-0.40 | 73.91% |
| 2014 | $-0.23 | -36.11% |
| 2013 | $-0.36 | -5.26% |
| 2012 | $-0.38 | 8.57% |
| 2011 | $-0.35 | 59.09% |
| 2010 | $-0.22 | 69.23% |
| 2009 | $-0.13 | -70.45% |
| 2008 | $-0.44 | 2.33% |
| 2007 | $-0.43 | -8.51% |
| 2006 | $-0.47 | -6.00% |
| 2005 | $-0.50 | 0.00% |
| 2004 | $-0.50 | 16.28% |
| 2003 | $-0.43 | -8.51% |
| 2002 | $-0.47 | -18.97% |
| 2001 | $-0.58 | -39.58% |
| 2000 | $-0.96 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 4,021.05% |
US
|
|
| $-7.07 | -1,960.53% |
US
|
|
| $-5.29 | -1,492.11% |
AU
|
|
| $12.88 | 3,289.50% |
BE
|
|
| $21.56 | 5,573.68% |
NL
|
Questions about Compugen Ltd.'s earnings per share (EPS)
What is Compugen Ltd.'s earnings per share (EPS)?
Compugen Ltd.'s earnings per share (EPS) over the last twelve months is $0.38, as of Jun 2026.
What was Compugen Ltd.'s earnings per share (EPS) in 2025?
In 2025, Compugen Ltd.'s earnings per share (EPS) was $0.38, compared with $-0.16 in 2024.
How has Compugen Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Compugen Ltd.'s earnings per share (EPS) was highest in 2025 ($0.38) and lowest in 2021 ($-0.41).
How does Compugen Ltd.'s earnings per share (EPS) compare with similar companies?
Compugen Ltd.'s earnings per share (EPS) ($0.38) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.